Upadacitinib
2 stories
-
healthUpadacitinib Maintains Safety Across Age Groups in Atopic Dermatitis
Long-term safety data from Phase III studies show upadacitinib is effective for moderate-to-severe atopic dermatitis across age groups, with specific considerations for older adults and higher doses.
-
healthUpadacitinib Shows High Hair Regrowth Efficacy in Severe Alopecia Areata
New Phase III trial data reveals the drug upadacitinib achieved significant scalp, eyebrow, and eyelash regrowth in adolescents and adults at 24 weeks.